



EirGenix, Inc.

2024 Annual Shareholders' Meeting Minutes

(This document is prepared in accordance with the Chinese version and is for reference only. In the event of any discrepancy between the English version and the Chinese version, the Chinese version shall prevail.)

Time and Date: 9:30 a.m., May 30, 2024

Place: International Conference Hall, R&D Center, Hsinchu Biomedical Park (2F, No. 8, Sec. 2, Shengyi Rd., Zhubei City, Hsinchu County).

Video supplementary Shareholders' meeting.

Visual communication platform used at the meeting:

The visual communication platform provided by the Taiwan Depository & Clearing Corporation (<https://stockservices.tdcc.com.tw>)

Total outstanding shares: 306,231,649 shares

Total shares represented by shareholders present in person or by proxy:

176,714,157 shares (including 101,267,135 shares represented by the shareholders by electronic voting method)

Percentage of shares held by shareholders present in person or by proxy:

57.70%

Chairman: Lee-Cheng Liu

Directors:

Formosa Laboratories, Inc., Representative: Cheng-Yu Cheng

National Development Fund, Executive Yuan, Representative: Hsiu-Hui Chen

Yao-Hwa Glass Co., Ltd, Management Commission, Representative: Ku-Sung Weng



Independent Director:

Ming-Thaur Chang (Convener of the Audit Committee)

Po-Chih Chen

Ming-Shen Chen

Fu-Shiow Yin

Other attendees:

COO: Chih-Jung Chang

CFO: Hsiu-Chuan Yang

PricewaterhouseCoopers Taiwan, CPA: Sheng-Wei Deng

Formosa Transnational Attorneys at Law, Lawyer: Yui-Ka Wang

Recorder: Pei-Fen Liu

The aggregate shareholding of the shareholders presents in person or by proxy constituted a quorum.

The Chairman called the meeting to order.

Chairman Remarks. (omitted)

I. Report Items

1. Report the Business Results of 2023.

Explanatory Notes: Please refer to Attachment 1.

2. Audit Committee's Review Report.

Explanatory Notes: Please refer to Attachment 2.

3. The 2023 Implementation Report for the Sound Business Plan.

Explanatory Notes:

The 2023 Implementation Report for the Sound Business plan is submitted to the Board of Directors for monitoring and reported to the Shareholders' Meeting. Please refer to Attachment 3.

4. Amendment to the Regulations Governing Procedure for Board of Directors Meetings.

Explanatory Notes:

It is proposed to amend the Regulations Governing Procedure for Board of Directors Meetings according to the official announcement from Financial Supervisory Commission on January 11, 2024 (official letter No. 1120383996). The comparison table is attached hereto as Attachment 4.

5. Discontinue the Private Security Offering Approved by 2023 Shareholders' Meeting.

Explanatory Notes:

- (1) It was authorized in the Shareholders' Meeting on May 31, 2023 that the Board of Directors may raise funds of at most 30,000,000 shares of common stocks by private placement depending on the market status and the Company's actual demands. The private placement shall be conducted one to three times within one year after the authorization starting from the resolution date.
- (2) As the termination date is near, in consideration of working capital and market status, the said private placement shall not be renewed and continued.

6. Remuneration Policy for the Directors of 2023.

Explanatory Notes: Please refer to Attachment 5.

II. Proposed Resolutions

1. Accept 2023 Financial Statements and the Business Report.

(Proposed by the Board of Directors)

Explanatory Notes:

- (1) EirGenix's 2023 Financial Statements, including consolidated financial statement and parent company only financial statement, were audited by independent auditors, Mr. Sheng-Wei Deng and Mr. Yu-Fang Yen, of PricewaterhouseCoopers Taiwan.
- (2) 2023 Business Report, Independent Auditors' Report, and the aforementioned Financial Statements are attached hereto as Attachments 1 and 6.

Voting Results:

Shares represented at the time of voting: 176,637,066 votes.

Voting Results	% of the total represented share present
Votes in favor: 173,353,380 votes (electronic: 99,656,562 votes, virtual: 0 votes)	98.14%
Votes against: 736,289 votes (electronic: 734,289 votes, virtual: 2,000 votes)	0.41%
Votes invalid: 0 vote	0.00%
Votes abstained: 2,547,397 votes (electronic: 747,504 votes, virtual: 126,780 votes)	1.44%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

2. Ratification of the 2023 Deficit Offset Proposal.

(Proposed by the Board of Directors)

Explanatory Notes:

- (1) EirGenix's 2023 financial statement showed an accumulated deficit is NT\$915,207,770. According to the Company's Articles of Incorporation, EirGenix does not intend to distribute dividends and bonuses this year.
- (2) It is proposed to compensate the total amount of the deficit by capital surplus; please refer to Attachment 7.

Voting Results:

Shares represented at the time of voting: 176,637,066 votes.

Voting Results	% of the total represented share present
Votes in favor: 173,296,463 votes (electronic: 99,597,645 votes, virtual: 2,000 votes)	98.10%
Votes against: 777,345 votes (electronic: 777,345 votes, virtual: 0 votes)	0.44%
Votes invalid: 0 vote	0.00%
Votes abstained: 2,563,258 votes (electronic: 763,365 votes, virtual: 126,780 votes)	1.45%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

III. Items for Discussion

1. Amendment to the Rules of Procedure for Shareholders Meetings

(Proposed by the Board of Directors)

Explanatory Notes:

It is proposed to amend the Rules of Procedure for Shareholders Meetings according to the official announcement from Financial Supervisory Commission on December 8, 2023 (official letter No. 1120385664). The comparison table is attached hereto as Attachment 8.

Voting Results:

Shares represented at the time of voting: 176,637,066 votes

Voting Results	% of the total represented share present
Votes in favor: 173,440,984 votes (electronic: 99,742,166 votes, virtual: 2,000 votes)	98.19%
Votes against: 699,270 votes (electronic: 699,270 votes, virtual: 0 votes)	0.39%
Votes invalid: 0 vote	0.00%
Votes abstained: 2,496,812 votes (electronic: 696,919 votes, virtual: 126,780 votes)	1.41%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

2. Adoption of the Issuance of Employee Restricted Stock Awards.

(Proposed by the Board of Directors)

Explanatory Notes:

(1) To attract and retain the professional talents required by EirGenix, to enhance the coherence of employees, EirGenix intends to issue a total of 1,400,000 shares at NT\$10 per share, and the total amount is NT\$14,000,000, according to Article 267 of the Company Act and related rules, including the Regulations Governing the Offering and Issuance of Securities by Securities Issuers to lay down the Regulations of 1st Employee Restricted Stocks in 2024. The actual number of shares to be issued will be resolved by the Board of Directors after the issuance of employee restricted stock awards is approved at the shareholders' meeting and by the competent authority.

(2) The content and items of the Restricted Employee Stock are as follows:

I. Issue Price: NT\$0 per share.

II. The Eligibility of Employee:

Only the Company's and controlling and subordinate company's regular employees are already employed when RSAs are granted. The term "controlling and subordinate company" is recognized in accordance with the standard from Financial Supervisory Commission (official letter No.1070121068).

III. Condition of Vesting:

Condition A: When the Company and employee's annual Key-Performance-Indicator (KPI) is at least 2.5, the employee will be eligible to receive 100% shares of the Company's restricted stock.

Condition B: Employees who join before Q3 of 2024 will be eligible to receive 100% shares of Company's restricted stock by the end of that year.

Condition C: Employees who join in Q4 of 2024 will be eligible to receive 100% shares of Company's restricted stock by the end of following year.

Condition D: Employees who join before Q3 of 2025 will be eligible to receive 100% shares of Company's restricted stock by the end of that year.

IV. Category of Restricted Employee Stock: Common shares of the company.

V. Measures to be taken when employees fail to meet the vesting conditions or in the event of inheritance: Where an executive fails to meet the vesting conditions, the Company will reclaim the granted RSAs and cancel the same at no extra cost to the Company; for exceptional events, including but not limited to inheritance, the Company will take measures as set forth in the Employee Restricted Stock Awards Rules.

VI. Number of Restricted Employee Stock eligible for subscription: The number for subscription to the respective employee is determined by the job level, salary, job tenure, performance, the contribution of the company's primary operation goals, the regulations at the subscription time and other caused as the reference.

VII. Restricted rights before employees meet the vesting conditions:

A. During the vesting period, the employee may not sell, pledge, transfer, give to another person, create any encumbrance on, or otherwise dispose of, restricted stock awards.

B. Voting right in Shareholders' Meetings and Dividend:
The same as common stock.

(3) Expected expense amount: The calculation of the expected expense amount is based on EirGenix 's outstanding 307,561,149 shares, including the estimated issue of 1,400,000 shares by restricted stock, and the average closing price in February 2024 is NT\$94.1 as fair value. If all employees achieve the condition, the total estimated expense amount is NT\$131,740 thousand. Based on the estimated issue date and given date are one to ten years, the annual amortized expense from 2024 to 2026, respectively, will be NT\$65,243 thousand, NT\$61,792 thousand and NT\$4,705 thousand. However, the actual amount will be calculated by the fair value on the given date and recognized related expenses in installments during the vested period.

(4) Dilution of EPS and other factors affecting shareholders' equity: EirGenix issues Restricted Employee Stock, representing 0.46% of an aggregate number of all

shares issued, the potential impact from the above-mentioned expenses to the Company's EPS is preliminarily estimated at approximately NT\$0.428 and from 2024 to 2026 are NT\$0.212, NT\$0.201, and NT\$0.015, respectively.

- (5) The Employee Restricted Stock issued may be deposited in a trust account.
- (6) It is proposed to the shareholders' meeting to authorize the board of directors to adjust the condition or regulation of the Employee Restricted Stock this time by law or as required by the competent authority and to also authorize the board of directors to decide the actual list of subscribers and the amount. The board of directors shall have full power to handle the issue without violating the principle of content agreed upon by the shareholder's meeting.

Voting Results:

Shares represented at the time of voting: 176,637,066 votes

Voting Results	% of the total represented share present
Votes in favor: 155,261,314 votes (electronic: 81,564,496 votes, virtual: 0 votes)	87.89%
Votes against: 3,616,703 votes (electronic: 3,614,703 votes, virtual: 2,000 votes)	2.04%
Votes invalid: 0 vote	0.00%
Votes abstained: 17,759,049 votes (electronic: 15,959,156 votes, virtual: 126,780 votes)	10.05%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

3. Approval of Private Placement of Securities.

(Proposed by the Board of Directors)

Explanatory Notes:

- (1) EirGenix has considered the timeliness of financing activities and the operational needs, and it will conduct private placements of common shares at a proper time, depending on the capital market. The maximum number of total shares issued will be 30,000,000 shares. It will be issued from one to three closings within one year of a resolution adopted by a shareholder meeting to increase the flexibility of EirGenix's financing activities. The anticipated issuance information is as follows. The actual issuance limit will be submitted to the shareholders' meeting to authorize the board of directors to determine it based on market conditions and the result of negotiations with investors.

Anticipated number of closings	Anticipated number of shares	It is estimated to conduct private placements for the capital increase in three closings. The unissued number of shares may be combined with the next closing or the anticipated number of shares of each closing may be combined together. The total number of shares issued shall not exceed 30,000,000 shares.
First time	10,000,000	
Second time	10,000,000	
Third time	10,000,000	

- (2) The issuance of private placements is conducted in accordance with the "Securities and Exchange Act" and "Directions for Public Companies Conducting Private Placements of Securities."
- (3) The basis and reasonableness of the private placement pricing:

The reference price is the simple average closing price of the common shares of the TWSE listed or TPEX listed company for either the 1, 3, or 5 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends or capital reduction; or the simple average closing price

of the common shares of the TWSE listed or TPEX listed company for the 30 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends, or capital reduction. The price shall be the higher of the above two calculations. The private placement pricing shall not be lower than 80% of the reference price.

(4) Source and the total amount of the private placement: The total estimated amount of offering securities to specific persons pursuant to Article 43-6 of the Securities Exchange Act.

(5) The method for selecting the specific persons and the anticipated benefits:

I. The placees of the private placement are strategic investors. In accordance with Article 43-6 of the Securities and Exchange Act and Taiwan Finance Certificate (1) No. 0910003455 issued by the Financial Supervisory Commission on June 13, 2002, it states to select those who are beneficial to the long-term development of the Company, and improve the operational performance, strengthen competitiveness, and generate benefits for existing shareholders' equity.

II. The method and purpose for selecting the placees: the purpose for the placees selected this time is to introduce strategic investors. The main targets are strategic investors who have developing experiences in biomedicine and health and can stabilize the Company's equity and capital structure.

III. The necessity of the placees: to accelerate the product developing efficiency as well as the process of the same drug series to complete the production line. By the comprehensive effect of expanding the market, it can establish EirGenix's unique status in the international biosimilars and CDMO field. In order to sustain EirGenix's operation and development, it is necessary to conduct private placement to introduce strategic investors by resolution.

IV. The relationship between the placees and the company: The placees haven't been arranged.

V. There is no significant change in managerial control within the one year period immediately preceding the day on which the board of directors resolves on the private placement and no significant change in managerial control after

the introduction of strategic investors through private placement.

VI. Anticipated benefits: improve EirGenix's operating scale, horizontal and vertical integration, and product or market development collaboration, assist EirGenix improving technology, efficiency, expand the operational scale, and improve the market status. It has positive benefits in creating EirGenix and shareholder value.

(6) The reasons for the necessity of conducting the private placement:

I. The reasons for not using a public offering:

With the considerations of the timeliness of financing activities and the uncertainty of the capital market, and the benefit for the Company's long-term operating development because of the transfer limit of the private placement common share, it plans to conduct the financial activities with the private placement.

II. The use of the funds for each closing of the private placement and the anticipated benefits:

A. The use of the funds for each closing of the private placement of common shares is to replenish operating capital for research and development expenses, plant expansion, horizontal and vertical integration, and other operational funding needs. It could strengthen EirGenix's financial structures and promote stable growth in operation.

B. Anticipated benefits: each closing is to act in concert with EirGenix's long-term development. It can cope with product development needs and expand operational scales to strengthen EirGenix's financial structure.

(7) The rights and obligations of the private placement of the common share are technically the same as the issued share. However, in accordance with the Securities and Exchange Act, the private placement of common shares may not be resold within three years after the delivery date except for the transfer objects in accordance with Article 43-8 of the Securities and Exchange Act. The private placement of common shares may be submitted to the shareholders meeting to authorize the board of directors to file an application to the Competent Authority with relevant regulations for supplemental public issuance and listed transactions

depending on the condition after three years of the delivery date and meet certain conditions of the competent authority.

- (8) The main content of the private placement plan, except with the actual issuance price, includes the number of shares for issuance, terms of issuance, the period for payment of subscription, the record date of the capital increase, planned item, estimated progress, estimated possible benefits, and all other matters related to the issuance plan. It is proposed to the shareholders' meeting to authorize the board of directors to adjust, establish, and handle according to market conditions. Any changes in the future due to changes in law and regulation, amendments instructed by the competent authority, and changes based on operational evaluation or objective circumstance shall be proposed to the shareholders' meeting to authorize the board of directors to take full charge of it.
- (9) According to Article 43-6 of the Securities and Exchange Act, the explanation of the Company's private placement of security resolutions can be found on the Market Observation Post System (<https://mops.twse.com.tw>) and EirGenix website (<http://www.eirgenix.com>).

Voting Results:

Shares represented at the time of voting: 176,637,066 votes

Voting Results	% of the total represented share present
Votes in favor: 173,228,675 votes (electronic: 99,531,857 votes, virtual: 0 votes)	98.07%
Votes against: 930,778 votes (electronic: 928,778 votes, virtual: 2,000 votes)	0.52%
Votes invalid: 0 vote	0.00%
Votes abstained: 2,477,613 votes (electronic: 677,720 votes, virtual: 126,780 votes)	1.40%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

4. Proposal to Release the Prohibition on Directors or Representatives of Directors from Participation in Competitive Business.

(Proposed by the Board of Directors)

Explanatory Notes:

- (1) According to Article 209 of the Company Act, “A director who does anything for himself or on behalf of another person that is within the scope of the company's business shall explain to the meeting of shareholders the essential contents of such an act and secure its approval.”
- (2) It is proposed that the shareholders meeting agree to release the prohibition on directors or representatives of directors from participation in the competitive business; please refer to the following table.

Name of Director/ Representative	Other Position
Director National Development Fund, Executive Yuan Representative: Hsiu-Hui Chen	Genovate Biotechnology Co., LTD. Representative of Corporate Director
Director Foxconn Technology Co., Ltd. Representative: Chun-Fu Lu	Refront IoMT Corp. Chairman

Voting Results:

Shares represented at the time of voting: 176,637,066 votes

Voting Results	% of the total represented share present
Votes in favor: 173,283,566 votes (electronic: 99,586,748 votes, virtual: 0 votes)	98.10%
Votes against: 880,507 votes (electronic: 878,507 votes, virtual: 2,000 votes)	0.49%
Votes invalid: 0 vote	0.00%
Votes abstained: 2,472,993 votes (electronic: 673,100 votes, virtual: 126,780 votes)	1.40%



*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

(Questions on Report Items, Proposed Resolutions and Items for Discussion raised by the shareholders and the management's responses were omitted.)

IV. Extemporaneous Motions

There being no other business and special motion, upon a motion duly made and seconded, the meeting was adjourned.

V. Meeting Adjourned

EirGenix, Inc.
2023 Annual Business Report

1. 2023 Business Result**(1) Business plan implementing results**

EirGenix was established on December 21, 2012 and listed in the market on June 28, 2019. It is a biotechnology and medical company focusing on biosimilars, drug discovery, and biopharmaceutical Contract Development and Manufacturing Organization (CDMO). The revenue was NT\$1,022,653 thousand in 2023 and NT\$1,481,017 thousand in 2022. The difference was mainly due to (1) deferred recognition of the milestone payments as a result of a delay in overseas medicine certificate, (2) facility expansion and equipment re-validation in Zhubei, and (3) the decrease in the market demand in CDMO. EirGenix holds the critical technology of biotechnological drug development and manufacture and is able to provide differentiated services with high value-added. Once production line expansion and upgrade have been completed, the growth momentum of revenues will resume. The consistent and stable operating income can cover part of the development expense for biosimilars. Various drug development projects are being implemented successively as planned. EirGenix's financial and business condition will rise substantially after obtaining the medicine certificate for mass production.

(2) Research and development status

- I. Establish competitive and complete production line development strategies:
 - A. EirGenix is currently developing the product for the treatment of HER2+ breast cancer. The dual-target treatment with Pertuzumab in combination with Trastuzumab for late-stage HER2+ breast cancer is gradually being used for early-stage breast cancer. EG1206A is one of the biosimilar leaders in the Pertuzumab market. This will also boost the market share of EG12014.
 - B. The exclusive licensee of EG12014 (Trastuzumab Biosimilar), Sandoz, maintains close communication with the FDA (Food and Drug Administration). Sandoz also works with EirGenix and suppliers for improvements based on the FDA's opinions in the shortest timeframe possible and files a resubmission after the response. Within

six months after the resubmission, the FDA will provide the review results in response to the application for approval. Meanwhile, the license of the EC (European Commission) and TFDA (Taiwan Food and Drug Administration) has been approved.

- C. The Phase III clinical trial of EG1206A (Pertuzumab Biosimilar) is expected to apply in 2024.
- D. The antibody-drug conjugate (ADC) EG12043 (TSY0110), jointly developed by the Company and Formosa Pharmaceuticals, expected to apply for Phase I clinical trial in 2024.

II. Outstanding development and manufacture technology of biotechnological drugs:

- A. EirGenix's Zhubei plant has passed the review by the FDA and obtained an EIR (Establishment Inspection Report) before the drug launch.
- B. The CDMO contracts signed in 2023 reached a total value of NT\$1.1 billion (US\$36 million). The CAGR (compound annual growth rate) was 27.3% in 2017-2023.
- C. In 2023, the mammalian capacity reached 25,500L and the microbial capacity reached 150 L. Building B at the Zhubei plant is expected to be completed in 2026, to increase the microbial capacity to 1,500 L. Meanwhile, a three-stage expansion of the mammalian plant which has 150,000 L capacity, is under planning at Ciaotou Science Park, Kaohsiung.
- D. Granted Accreditation Certificate of Foreign Drug Manufacturer by Japan MHLW, with the accreditation category of "biological products" and effective date from October 24, 2022 to October 30, 2027.

III. Affirmation on business performance:

- A. Received the approval letter from TFDA that the API Trastuzumab has obtained the license and the DMF number.
- B. The Phase I clinical trial of the biosimilar EG1206A has met its primary endpoint and showed Pharmacokinetic biosimilarity.
- C. Received the approval letter from Ministry of Health and Welfare for the biosimilar drug EIRGASUN 150 mg powder for concentrate for infusion.
- D. Won the highest honor of "New Taipei City Family Friendly Work Equality Measures" in 2023.
- E. The biosimilar drug, "EIRGASUN vial 150 mg", has been approved by National Health Insurance Administration to be enrolled in the reimbursement system.

- F. Received a positive CHMP opinion for the biosimilar drug EG12014 licensed.
- G. Top 5% among TPEX-listed companies in the 9th Corporate Governance Evaluation.
- H. Received the approval letter from EC for EG12014 licensed.
- I. EIRGASUN vial 150 mg won the Golden award of National Pharmaceutical Technology Research Development Award in 2023.

(3) Financial revenue and expenditure and profitability analysis

The annual operating incomes are NT\$ 1,022,653 thousand dollars, which are mainly contributed by CDMO business and cooperative development revenue. The gross profit is NT\$ 236,741 thousand dollars with a 23% gross margin rate. The major expenditures in 2023 were biosimilars development and research expenses. The reason for that is because the products are still in the development stage and require more investments for research and development funds, such as clinical study expenses, research and development material expenses, and research and development staff salaries. CDMO sales and other revenues are still unable to fully cover the research and development expenditures mentioned previously at this point, which is the main reason that caused EirGenix's loss. The investment of research and development expenditures now is to accumulate the energy for future profit growth after the product launches.

Unit: %

Item \ Year		2023	2022
Financial Structure	Debt Ratio	10.26	9.83
	Long Term Funds to property, plant, and equipment	313.25	426.10
Solvency	Current Ratio	977.92	1,133.94
	Quick Ratio	868.41	1,015.88
Profitability	Rate of return on assets	(7.88)	(0.93)
	Rate of return on equity	(8.84)	(1.09)
	Net Profit Margin	(89.49)	(7.80)
	Earnings per share (NT\$)	(\$3.00)	(\$0.38)

(4) Budget implementation status

EirGenix had only set up an internal budget goal for 2023 and did not disclose the financial forecast to the public. The overall budget implementation has met the goal.

2. 2024 Business plan summary

(1) Business policy

EirGenix's business policy is to maintain the sustainable growth since its establishment. It came up with three major service items after considering the three factors of the sales and developing time of drugs, risk value, and potential returns, three stages of the business focus have been set: 1. Contract Development and Manufacturing Organization (CDMO); 2. Biosimilar Development, and 3. Me too and Novel biologics development to make the best of EirGenix's cGMP production factory, equipment, and high-end technology human resources.

(2) Estimated sales, and its basis, and important production and sales policy

EirGenix's biosimilars in development are still in the developing stage. The main revenue resource comes from Contract Development and Manufacturing Organization and authorized product collaborations. The senior management team proposes the overall goal and strategy, and the research and development team make various development project plans. The project schedule for plan implementation and sales projection is made by feasibility analysis, market potential and financial evaluation.

3. EirGenix's future development strategy

(1) The short-term development strategy is "Build up the foundation and move forward step by step." The strategy plans for products in-development and CDMO sales & marketing development are as follows:

- A. EG12014 approved by the FDA and other countries in Aisa.
- B. EG12014 (HERWENDA® - Sandoz | EIRGASUN® - EirGenix) market launch.
- C. EG1206A submit the application for Phase III trials.
- D. Application for EG12043 (TSY0110) clinical trials (IND).
- E. EG1211X pre-clinical preparation completed.
- F. Expansion of Building B at Zhubei plant to increase the microbial capacity to 1,500 L in 2026.

(2) The medium and long-term development strategy is "Products are developing and launching one after another to promote stable growth in revenue. The strategy plans for products in-development and CDMO sales development are as follows:

- A. New dosage forms or new drug delivery systems of biosimilars: development of Trastuzumab high-concentration subcutaneous doses; planning for the

development of EG12014+EG1206A dual-targeting high-concentration subcutaneous doses. The successful development of high-concentration subcutaneous doses will strengthen the product market share of these products and enable EirGenix as the primary supplier of biosimilar drugs for the treatment of HER2+ breast cancer.

- B. Developing the biosimilar for the treatment of blood cancer are currently ongoing. According to the development schedule, one new product will be introduced to the market each one to two years starting in 2027. Hence, a three-stage expansion of the mammalian capacity by 150,000L is under planning at Ciaotou Science Park, Kaohsiung. The new capacity can be used to manufacture in-house developed drugs and accept customers' orders for commercial and scale production.

4. Effects by the external competitive environment, legal environment, and overall business environment

The mission of EirGenix at the beginning is to provide high-quality and cost-effective Contract Development and Manufacturing Organization and develop biosimilars with commercial values. The medium to long-term goal is focusing on Niche Biologics development to benefit the human and the society and improve the life quality. EirGenix insists on making the technology first with excellent quality as the foundation and be responsible for customer's success. The goal is to become an international biotechnology and medicine company that begins in Taiwan and focuses on the global market.

We would like to thank all of the shareholders, customers, and collaborating business partners for encouraging and supporting us, as well as the contribution and hard work from our employees. Together it brings prosperity and constant growth for EirGenix.

EirGenix, Inc.

Chairman & President: Lee-Cheng Liu

Head of Accounting Department: Hsiu-Chuan Yang

EirGenix, Inc.
Audit Committee's Review Report

The Board of Directors has prepared EirGenix's 2023 Business Report, Financial Statement, and Deficit Offset Statement. The CPA Sheng-Wei Deng and Yu-Fang Yen of PricewaterhouseCoopers Taiwan was retained to audit EirGenix's Financial Statement and has issued an audit report relating to the Financial Statement.

The Business Report, Financial Statement, and Deficit Compensation Statement have been reviewed and determined to be correct and accurate by the Audit Committee member of EirGenix. According to relevant requirements of the Securities and Exchange Act and the Company Act, we hereby submit this report.

To

EirGenix, Inc. 2024 Annual Shareholders' Meeting

EirGenix, Inc.

Chairman of Audit Committee: Ming-Thaur Chang

Member of Audit Committee: Po-Chih Chen

Member of Audit Committee: Fu-Shiow Yin

Member of Audit Committee: Ming-Shen Chen

March 8, 2024

EirGenix, Inc.
2023 Implementation Report for the Sound Business Plan

Unit: NT thousand dollars

Item	Actual	Estimate	Increase (decrease) amount	Increase (decrease) percentage
Operating Revenue	1,022,653	1,030,186	(7,533)	(0.73%)
Operating Cost	785,912	803,889	(17,977)	(2.24%)
Gross Profit	236,741	226,297	10,444	4.62%
Operating Expenses	1,268,718	1,238,252	30,466	2.46%
Operating Income (Loss)	(1,031,977)	(1,011,955)	20,022	1.98%
Non- operating income (loss)	118,327	132,318	(13,991)	(10.57%)
Net loss before income tax	(913,650)	(879,637)	34,013	3.87%

EirGenix achieved 99.27% of the target for 2023 revenues. The gross profit exceeded the estimation by NT\$10,444 thousand. The 2023 operating expenses were NT\$30,466 thousand over than estimated, primarily due to the R&D expense on self-development product was over than anticipated. The operating loss were NT\$20,022 thousand over than the estimation, mainly as a result of unfavorable movements of R&D expenses.

In addition, the non-operating income was NT\$13,991 thousand less than estimated, primarily due to the unfavorable movements of the fluctuations in international exchange rate, and lead to the effects on foreign exchange gains and losses.

In conclusion, the net loss before tax increased by NT\$34,013 thousand compared to the estimated amount due to the unfavorable movements of R&D expenses. Therefore, implementation status of EirGenix's 2023 sound operation plan was reasonable.

Comparison Table for the Regulations Governing Procedure for Board of Directors Meetings

After the Revision	Before the Revision	Explanation
Article 10 If one-half of all the directors are not in attendance at the appointed meeting time, the chair may announce postponement of the meeting time <u>on the same day</u>, provided that no more than two such postponements may be made, and the total length of postponement time may not exceed one hour. If the quorum is still not met after the postponement time, the chairman shall announce the adjournment of the meeting and shall not make the tentative resolution on the proposal. The meeting which has been announced the adjournment by chairman, the chair shall reconvene the meeting in accordance with the procedures in Article 3 and the meeting can be held again. The term "all board directors " as used in the preceding paragraph and in Article 16, paragraph 3, subparagraph 2 shall be calculated as the number of directors then in office.	Article 10 If one-half of all the directors are not in attendance at the appointed meeting time, the chair may announce postponement of the meeting time, provided that no more than two such postponements may be made, and the total length of postponement time may not exceed one hour. If the quorum is still not met after the postponement time, the chairman shall announce the adjournment of the meeting and shall not make the tentative resolution on the proposal. The meeting which has been announced the adjournment by chairman, the chair shall reconvene the meeting in accordance with the procedures in Article 3 and the meeting can be held again. The term "all board directors " as used in the preceding paragraph and in Article 16, paragraph 3, subparagraph 2 shall be calculated as the number of directors then in office.	The revisions to those Article are proposed in accordance with the amendment to “Regulations Governing Procedure for Board of Directors Meetings of Public Companies” by the ruling letter JinGuan-Zheng-Fa-Zi No. 1120383996 dated January 11, 2024, issued by the Financial Supervisory Commission.
Article 11 In principle, a board meeting shall follow the agenda given in the meeting notice. However, the agenda may be changed with the approval of a majority of directors	Article 11 In principle, a board meeting shall follow the agenda given in the meeting notice. However, the agenda may be changed with the approval of a majority of directors	

in attendance at the board meeting. The chair may not declare the meeting adjourned prior to completion of deliberation on the meeting agenda of the preceding paragraphs (including extraordinary motions). At any time during the course of a board meeting, if the number of directors sitting at the meeting does not constitute a majority of the attending directors, then upon the motion by a director sitting at the meeting, the chair shall declare a suspension of the meeting, in which case previous article shall apply mutatis mutandis. <u>During the proceedings of a board meeting, if the chair is unable to chair the meeting or fails to declare the meeting closed as provided in paragraph 2, the provisions of Article 7, paragraph 3 shall apply mutatis mutandis to the selection of the deputy to act in place thereof.</u>	in attendance at the board meeting. The chair may not declare the meeting adjourned prior to completion of deliberation on the meeting agenda of the preceding paragraphs (including extraordinary motions). At any time during the course of a board meeting, if the number of directors sitting at the meeting does not constitute a majority of the attending directors, then upon the motion by a director sitting at the meeting, the chair shall declare a suspension of the meeting, in which case previous article shall apply mutatis mutandis.	
Article 21 The Procedure was enacted on July 24th, 2013. The 1st amendment was made on August 8th, 2016. The 2nd amendment was made on March 23rd, 2018. The 3rd amendment was made on March 20th, 2020. The 4th amendment was made on March 10th, 2023. <u>The 5th amendment was made on March 8th, 2024.</u>	Article 21 The Procedure was enacted on July 24th, 2013. The 1st amendment was made on August 8th, 2016. The 2nd amendment was made on March 23rd, 2018. The 3rd amendment was made on March 20th, 2020. The 4th amendment was made on March 10th, 2023.	Add the date of amendments.

Attachment 5

Remuneration Policy for the Directors

If the Company has net profit in this fiscal year, the Company shall set aside 3% (inclusive) or less of its profits as bonus to Directors. The distribution of director remuneration shall be heard by over two-thirds of the Board of Directors, be voted in favor for implementation by over one-half of the directors present and represented, and also be reported at the shareholders' meeting. The Company shall first offset its losses in previous years that have not been previously offset, and then set aside annual profits as a bonus to Directors.

EirGenix did not distribute bonuses to directors for the aforementioned two years. Director Remuneration is the travel expenditure spent to attend Board. The compensation paid to the independent directors is on a fixed monthly basis or for the purposes of carrying out their duties. Remuneration paid to the general manager is handled determined by considering the position of the chairman in the Company, the responsibility they assume, and their contribution to the Company, as well as industry benchmarks. The remuneration is proposed by the Company to the Remuneration Committee for approval and presented to the Board of Directors for review.

Unit : NTS thousands ; %

Title	Name	Remuneration								Ratio of Total Remuneration (A+B+C+D) to Net Income (%)		Relevant Remuneration Received by Directors Who are Also Employees								Ratio of Total Compensation (A+B+C+D+E+F+G) to Net Income (%)		Remuneration from ventures other than subsidiaries or from the parent company
		Base Compensation (A)		Severance Pay (B)		Directors Compensation(C)		Allowances (D)				Salary, Bonuses, and Allowances (E)		Severance Pay (F)		Employee Compensation (G)						
		The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company		Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements		
	Chairman Lee-Cheng Liu	0	0	0	0	0	0	30	30	30 (0.003)	30 (0.003)	37,408 (Note)	37,408 (Note)	0	0	0	0	0	0	37,438 (4.09)	37,438 (4.09)	0
	Director National Development Fund, Executive Yuan	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Director Representative Hsiu-Hui Chen	0	0	0	0	0	0	30	30	30 (0.003)	30 (0.003)	0	0	0	0	0	0	0	0	30 (0.003)	30 (0.003)	0
	Director Formosa Laboratories, Inc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Director Representative Cheng-Yu Cheng	0	0	0	0	0	0	25	25	25 (0.003)	25 (0.003)	0	0	0	0	0	0	0	0	25 (0.003)	25 (0.003)	0
	Director Yao-Hwa Glass Co., Ltd, Management Commission	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Director Representative Ku-Sung Weng	0	0	0	0	0	0	25	25	25 (0.003)	25 (0.003)	0	0	0	0	0	0	0	0	25 (0.003)	25 (0.003)	0

Title	Name	Remuneration								Ratio of Total Remuneration (A+B+C+D) to Net Income (%)		Relevant Remuneration Received by Directors Who are Also Employees								Ratio of Total Compensation (A+B+C+D+E+F+G) to Net Income (%)		Remuneration from ventures other than subsidiaries or from the parent company
		Base Compensation (A)		Severance Pay (B)		Directors Compensation(C)		Allowances (D)				Salary, Bonuses, and Allowances (E)		Severance Pay (F)		Employee Compensation (G)						
		The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company		Companies in the consolidated financial statements		The company	Companies in the consolidated financial statements	
																Cash	Stock	Cash	Stock			
Director Foxconn Technology Co., Ltd.		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Director Representative Yu-Ting Chen		0	0	0	0	0	0	25	25	25 (0.003)	25 (0.003)	0	0	0	0	0	0	0	0	25 (0.003)	25 (0.003)	0
Director Representative Chun-Fu Lu		0	0	0	0	0	0	25	25	25 (0.003)	25 (0.003)	0	0	0	0	0	0	0	0	25 (0.003)	25 (0.003)	0
Former Director Representative Jih-Luh Tang		0	0	0	0	0	0	5	5	5 (0.0005)	5 (0.0005)	0	0	0	0	0	0	0	0	5 (0.0005)	5 (0.0005)	0
Independent Director Ming-Thaur Chang		960	960	0	0	0	0	30	30	990 (0.11)	990 (0.11)	0	0	0	0	0	0	0	0	990 (0.11)	990 (0.11)	0
Independent Director Po-Chih Chen		960	960	0	0	0	0	25	25	985 (0.11)	985 (0.11)	0	0	0	0	0	0	0	0	985 (0.11)	985 (0.11)	0
Independent Director Fu-Shiow Yin		960	960	0	0	0	0	30	30	990 (0.11)	990 (0.11)	0	0	0	0	0	0	0	0	990 (0.11)	990 (0.11)	0
Independent Director Ming-Shen Chen		960	960	0	0	0	0	30	30	990 (0.11)	990 (0.11)	0	0	0	0	0	0	0	0	990 (0.11)	990 (0.11)	0

Note : Including the share-based payment.

1. Please describe the policy, system, standard, and structure of remuneration to independent directors, and the correlation between duties, risk, and time input with the amount of remuneration:

If the Company has net profit in this fiscal year, the Company shall set aside 3% (inclusive) or less of its profits as bonus to Directors. The distribution of director remuneration shall be heard by over two-thirds of the Board of Directors, be voted in favor for implementation by over one-half of the directors present and represented and be reported at the shareholders' meeting.

The Company did not pay any director remuneration during the previous two years. Directors only received traffic allowances for conducting businesses. Independent directors receive fixed emoluments for performing businesses. The aforesaid traffic allowances and emoluments for conducting businesses have been reviewed by Remuneration Committee and approved by the Board of Directors.

2. In addition to the above remuneration, director remuneration shall be disclosed as follows when received from companies included in the consolidated financial statements in the most recent year to compensate directors for their services, such as being independent contractors: None.

Attachment 6

Financial Statements and Independent Auditors' Report

EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2023 AND 2022
(Expressed in thousands of New Taiwan dollars)

Assets		Notes	December 31, 2023		December 31, 2022	
			AMOUNT	%	AMOUNT	%
Current assets						
1100	Cash and cash equivalents	6(1)	\$ 5,053,183	45	\$ 6,126,885	52
1136	Current financial assets at amortised cost	6(3)	500,000	5	1,000,000	9
1140	Current contract assets	6(19) and 7	293,694	3	234,399	2
1150	Notes receivable, net	6(4)	19	-	-	-
1170	Accounts receivable, net	6(4)	253,390	2	32,782	-
1180	Accounts receivable, net-related parties	7	2,636	-	-	-
1200	Other receivables		20,497	-	24,944	-
1220	Current income tax assets		17,648	-	5,963	-
130X	Inventories	6(5)	680,637	6	739,463	6
1410	Prepayments	6(6)	93,802	1	123,442	1
11XX	Total current assets		6,915,506	62	8,287,878	70
Non-current assets						
1510	Non-current financial assets at fair value through profit or loss	6(2) and 7	80,298	1	61,420	1
1517	Non-current financial assets at fair value through other comprehensive income	6(7)	325,887	3	279,325	2
1535	Non-current financial assets at amortised cost	6(3) and 8	40,720	-	41,123	-
1600	Property, plant and equipment, net	6(8), 7 and 8	3,337,685	30	2,608,848	22
1755	Right-of-use assets	6(9)	329,236	3	325,330	3
1780	Intangible assets	6(10)	28,269	-	28,067	-
1990	Other non-current assets	6(8)(11) and 8	104,958	1	215,165	2
15XX	Total non-current assets		4,247,053	38	3,559,278	30
1XXX	Total assets		\$ 11,162,559	100	\$ 11,847,156	100

(Continued)



EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2023 AND 2022
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity			December 31, 2023		December 31, 2022	
Notes			AMOUNT	%	AMOUNT	%
Current liabilities						
2130	Current contract liabilities	6(19) and 7	\$ 56,766	-	\$ 150,475	1
2170	Accounts payable		79,556	1	134,607	1
2200	Other payables	6(12)	530,299	5	407,387	4
2220	Other payables - related parties	7	7,993	-	7,732	-
2230	Current tax liabilities		992	-	761	-
2280	Current lease liabilities		28,622	-	26,826	-
2399	Other current liabilities		2,937	-	3,104	-
21XX	Total current liabilities		707,165	6	730,892	6
Non-current liabilities						
2540	Long-term borrowings	6(13) and 8	120,460	1	120,460	1
2570	Deferred tax liabilities	6(25)	1,380	-	874	-
2580	Non-current lease liabilities		316,085	3	311,758	3
2600	Other non-current liabilities		6	-	294	-
25XX	Total non-current liabilities		437,931	4	433,386	4
2XXX	Total liabilities		1,145,096	10	1,164,278	10
Equity						
Capital		6(16)				
3110	Common stock		3,060,516	28	3,043,358	26
Capital reserve		6(17)				
3200	Capital surplus		7,830,216	70	7,734,141	65
Accumulated deficit		6(18)				
3350	Accumulated deficit		(915,208)	(8)	(115,540)	(1)
Other equity interest						
3400	Other equity interest		41,939	-	20,919	-
3XXX	Total Equity		10,017,463	90	10,682,878	90
Significant contingent liabilities and unrecognised contract commitments		9				
Significant events after the balance sheet date		11				
3X2X	Total Liabilities and Equity		\$ 11,162,559	100	\$ 11,847,156	100

The accompanying notes are an integral part of these consolidated financial statements.



EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2023 AND 2022
(Expressed in thousands of New Taiwan dollars, except for loss per share)

		Year ended December 31			
Items	Notes	2023		2022	
		AMOUNT	%	AMOUNT	%
4000 Operating Revenue	6(19) and 7	\$ 1,022,653	100	\$ 1,481,017	100
5000 Operating Costs	6(5)(10)(24) and 7	(785,912)	(77)	(724,565)	(49)
5900 Gross Profit		<u>236,741</u>	<u>23</u>	<u>756,452</u>	<u>51</u>
Operating Expenses	6(10)(24) and 7				
6100 Sales and marketing expenses		(62,232)	(6)	(50,844)	(3)
6200 General and administrative expenses		(254,196)	(25)	(236,675)	(16)
6300 Research and development expenses		(952,290)	(93)	(800,144)	(54)
6450 Reversal of credit impairment loss(expected credit impairment loss)	12(2)	-	-	392	-
6000 Total operating expenses		(1,268,718)	(124)	(1,087,271)	(73)
6900 Operating Loss		(1,031,977)	(101)	(330,819)	(22)
Non-operating Income and Expenses					
7100 Interest income	6(3)(20)	134,471	13	59,584	4
7010 Other income	6(21)	5,439	-	37,644	2
7020 Other gains and losses	6(2)(9)(22)	(11,180)	(1)	128,915	9
7050 Finance costs	6(9)(23) and 7	(10,403)	(1)	(9,639)	(1)
7000 Total non-operating income and expenses		<u>118,327</u>	<u>11</u>	<u>216,504</u>	<u>14</u>
7900 Loss before Income Tax		(913,650)	(90)	(114,315)	(8)
7950 Income tax	6(25)	(1,558)	-	(1,225)	-
8200 Net Loss		<u>(\$ 915,208)</u>	<u>(90)</u>	<u>(\$ 115,540)</u>	<u>(8)</u>
Other Comprehensive Income					
Components of other comprehensive income that will not be reclassified to profit or loss					
8316 Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	6(7)	\$ 45,939	5	\$ 59,091	4
8310 Other comprehensive income(loss) that will not be reclassified to profit or loss		<u>45,939</u>	<u>5</u>	<u>59,091</u>	<u>4</u>
Components of other comprehensive income that will be reclassified to profit or loss					
8361 Exchange differences on translation of foreign financial statements		220	-	220	-
8399 Income tax related to components of other comprehensive income that will be reclassified to profit or loss	6(25)	(41)	-	-	-
8360 Other comprehensive income(loss) that will be reclassified to profit or loss		<u>179</u>	<u>-</u>	<u>220</u>	<u>-</u>
8300 Other Comprehensive Income		<u>\$ 46,118</u>	<u>5</u>	<u>\$ 59,311</u>	<u>4</u>
8500 Total Comprehensive Loss		<u>(\$ 869,090)</u>	<u>(85)</u>	<u>(\$ 56,229)</u>	<u>(4)</u>
Loss per share	6(26)				
9750 Loss per share		<u>(\$ 3.00)</u>		<u>(\$ 0.38)</u>	

The accompanying notes are an integral part of these consolidated financial statements.



FIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2023 AND 2022
(Expressed in thousands of New Taiwan dollars)

Equity attributable to owners of the parent												
Notes	Capital Reserves								Other equity interest			
	Common stock	Additional paid-in capital	Donated assets received	Employee stock options	Capital surplus, stock options	Restricted stock to employees	Capital surplus, others	Accumulated deficit	Exchange differences on translation of foreign financial statements	Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	Unearned compensation	Total equity
<u>Year ended December 31, 2022</u>												
Balance at January 1, 2022	\$ 3,003,845	\$ 10,313,563	\$ 2,036	\$ 41,958	\$ 3,467	\$ 114,928	\$ -	(\$ 2,973,500)	(\$ 237)	\$ 5,831	(\$ 83,140)	\$ 10,428,751
Loss for 2022	-	-	-	-	-	-	-	(115,540)	-	-	-	(115,540)
Other comprehensive income (loss)	6(7)	-	-	-	-	-	-	-	220	59,091	-	59,311
Total comprehensive income (loss)		-	-	-	-	-	-	(115,540)	220	59,091	-	(56,229)
Capital surplus used to offset accumulated deficit	6(18)	-	(2,971,464)	(2,036)	-	-	-	2,973,500	-	-	-	-
Compensation costs of share-based payments	6(15)	-	-	-	61,651	-	871	-	-	-	92,790	155,312
Employee stock options exercised	6(15)(16)	10,523	26,467	(8,320)	-	-	-	-	-	-	-	28,670
Issuance of employee restricted stocks	6(15)(16)	6,318	-	-	-	47,318	-	-	-	-	(53,636)	-
Redemption of employee restricted stocks	6(15)(16)	(2,260)	-	-	-	2,260	-	-	-	-	-	-
Restricted stocks vested		-	59,358	-	-	(59,358)	-	-	-	-	-	-
Conversion of convertible bonds	6(16)	24,932	104,904	-	(3,462)	-	-	-	-	-	-	126,374
Redemption of convertible bonds		-	-	-	(5)	-	5	-	-	-	-	-
Balance at December 31, 2022	<u>\$ 3,043,358</u>	<u>\$ 7,532,828</u>	<u>\$ -</u>	<u>\$ 95,289</u>	<u>\$ -</u>	<u>\$ 105,148</u>	<u>\$ 876</u>	<u>(\$ 115,540)</u>	<u>(\$ 17)</u>	<u>\$ 64,922</u>	<u>(\$ 43,986)</u>	<u>\$ 10,682,878</u>
<u>Year ended December 31, 2023</u>												
Balance at January 1, 2023	\$ 3,043,358	\$ 7,532,828	\$ -	\$ 95,289	\$ -	\$ 105,148	\$ 876	(\$ 115,540)	(\$ 17)	\$ 64,922	(\$ 43,986)	\$ 10,682,878
Loss for the 2023	-	-	-	-	-	-	-	(915,208)	-	-	-	(915,208)
Other comprehensive income (loss)	6(7)	-	-	-	-	-	-	-	179	45,939	-	46,118
Total comprehensive income (loss)		-	-	-	-	-	-	(915,208)	179	45,939	-	(869,090)
Capital surplus used to offset accumulated deficit	6(18)	-	(114,664)	-	-	-	(876)	115,540	-	-	-	-
Compensation costs of share-based payments	6(15)	-	-	-	84,285	-	-	-	-	-	96,615	180,900
Employee stock options exercised	6(15)(16)	7,270	25,769	(10,264)	-	-	-	-	-	-	-	22,775
Employee stock options expired	6(15)	-	-	(1,810)	-	-	1,810	-	-	-	-	-
Issuance of employee restricted stocks	6(15)(16)	11,818	-	-	-	109,895	-	-	-	-	(121,713)	-
Redemption of employee restricted stocks	6(15)(16)	(1,930)	-	-	-	1,930	-	-	-	-	-	-
Restricted stocks vested		-	71,119	-	-	(71,119)	-	-	-	-	-	-
Balance at December 31, 2023	<u>\$ 3,060,516</u>	<u>\$ 7,515,052</u>	<u>\$ -</u>	<u>\$ 167,500</u>	<u>\$ -</u>	<u>\$ 145,854</u>	<u>\$ 1,810</u>	<u>(\$ 915,208)</u>	<u>\$ 162</u>	<u>\$ 110,861</u>	<u>(\$ 69,084)</u>	<u>\$ 10,017,463</u>

The accompanying notes are an integral part of these consolidated financial statements.



EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2023 AND 2022
(Expressed in thousands of New Taiwan dollars)

		Year ended December 31	
	Notes	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES			
Loss before tax		(\$ 913,650)	(\$ 114,315)
Adjustments			
Adjustments to reconcile profit (loss)			
Depreciation	6(8)(9)(24)	227,544	189,100
Amortization	6(10)(24)	11,296	16,184
Net loss (gain) on financial assets or liabilities at fair value	6(2)(22)	1,122	(2,863)
Interest expense	6(23)	10,403	9,639
Interest income	6(20)	(134,471)	(59,584)
Dividend income	6(21)	(475)	-
Compensation costs of share-based payments	6(15)(24)	180,900	155,312
Loss on lease modification	6(9)(22)	413	709
Loss on redemption of convertible bonds	6(22)	-	3
Reversal of credit impairment loss(expected credit impairment loss)	12(2)	-	(392)
Changes in operating assets and liabilities			
Changes in operating assets			
Contract assets		(59,295)	(63,802)
Notes receivable, net		(19)	1,139
Accounts receivable, net		(220,608)	46,084
Accounts receivable, net-related parties		(2,636)	546
Other receivables		6,736	(13,790)
Inventories		58,826	(324,025)
Prepayments		29,640	(17,394)
Other current assets		-	1,555
Changes in operating liabilities			
Contract liabilities		(93,709)	(93,551)
Accounts payable		(55,051)	48,151
Other payables		(5,604)	33,854
Other payables - related parties		261	2,037
Other current liabilities		(167)	(1,818)
Cash outflow generated from operations		(958,544)	(187,221)
Interest received		132,183	55,231
Interest paid		(10,386)	(9,316)
Dividends received		475	-
Income tax received		1,128	-
Income tax paid		(13,412)	(6,212)
Net cash flows used in operating activities		(848,556)	(147,518)

(Continued)



EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2023 AND 2022
(Expressed in thousands of New Taiwan dollars)

		Year ended December 31	
	Notes	2023	2022
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of financial assets at fair value through profit or loss	6(2)	\$ -	(\$ 58,390)
Acquisition of financial assets at fair value through other comprehensive income	6(7)	(623)	(208,627)
Acquisition of financial assets at amortised cost		(3,700,000)	(1,032,516)
Proceeds from disposal of financial assets at amortised cost		4,200,403	1,636,640
Acquisition of property, plant and equipment	6(8)(27)	(575,270)	(345,792)
Acquisition of intangible assets	6(10)(27)	(15,142)	(8,652)
Decrease in other financial assets		-	27,334
Decrease (increase) in refundable deposits (shown as other non-current assets)		56,253	(778)
Increase in prepayments for investments (shown as other non-current assets)		(46,270)	(20,000)
Increase in prepayments for business facilities (shown as other non-current assets)	6(8)	(138,453)	(433,952)
Increase in other non-current assets		84	(31,317)
Net cash flows used in investing activities		(219,018)	(476,050)
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Repayments of bonds	6(28)	-	(200)
Proceeds from long-term borrowings	6(28)	-	120,460
Decrease (increase) in guarantee deposits received (shown as other non-current liabilities)	6(28)	(288)	294
Repayments of lease principal	6(28)	(29,307)	(24,435)
Employee stock options exercised		22,775	28,669
Net cash flows (used in) from financing activities		(6,820)	124,788
Effect of exchange rate		692	281
Net decrease in cash and cash equivalents		(1,073,702)	(498,499)
Cash and cash equivalents at beginning of year		6,126,885	6,625,384
Cash and cash equivalents at end of year		\$ 5,053,183	\$ 6,126,885

The accompanying notes are an integral part of these consolidated financial statements.



EIRGENIX INC.
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2023 AND 2022
(Expressed in thousands of New Taiwan dollars)

Assets		Notes	December 31, 2023		December 31, 2022	
			AMOUNT	%	AMOUNT	%
Current assets						
1100	Cash and cash equivalents	6(1)	\$ 5,048,604	45	\$ 6,108,994	52
1136	Current financial assets at amortised cost	6(3)	500,000	5	1,000,000	9
1140	Current contract assets	6(20) and 7	293,694	3	234,399	2
1150	Notes receivable, net	6(4)	19	-	-	-
1170	Accounts receivable, net	6(4)	253,390	2	32,782	-
1180	Accounts receivable, net-related parties	7	2,636	-	-	-
1200	Other receivables		20,497	-	24,944	-
1220	Current income tax assets		17,648	-	5,963	-
130X	Inventories	6(5)	680,637	6	739,463	6
1410	Prepayments	6(6)	92,677	1	122,502	1
11XX	Total current assets		6,909,802	62	8,269,047	70
Non-current assets						
1510	Non-current financial assets at fair value through profit or loss	6(2) and 7	80,298	1	61,420	1
1517	Non-current financial assets at fair value through other comprehensive income	6(7)	325,887	3	279,325	2
1535	Non-current financial assets at amortised cost	6(3) and 8	40,720	-	41,123	-
1550	Investments accounted for using equity method	6(8)	7,743	-	5,200	-
1600	Property, plant and equipment, net	6(9), 7 and 8	3,337,069	30	2,607,958	22
1755	Right-of-use assets	6(10)	329,236	3	325,330	3
1780	Intangible assets	6(11)	28,269	-	28,067	-
1990	Other non-current assets	6(9)(12) and 8	104,764	1	214,887	2
15XX	Total non-current assets		4,253,986	38	3,563,310	30
1XXX	Total assets		\$ 11,163,788	100	\$ 11,832,357	100

(Continued)



EIRGENIX INC.
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2023 AND 2022
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity			December 31, 2023		December 31, 2022			
			Notes	AMOUNT	%	AMOUNT	%	
Current liabilities								
2130	Current contract liabilities	6(20) and 7	\$	56,766	-	\$	150,475	2
2170	Accounts payable			79,556	1		134,607	1
2200	Other payables	6(13)		519,762	5		384,682	3
2220	Other payables - related parties	7		20,751	-		16,397	-
2280	Current lease liabilities			28,622	-		26,826	-
2399	Other current liabilities			2,937	-		3,106	-
21XX	Total current liabilities			708,394	6		716,093	6
Non-current liabilities								
2540	Long-term borrowings	6(14) and 8		120,460	1		120,460	1
2570	Deferred tax liabilities	6(26)		1,380	-		874	-
2580	Non-current lease liabilities			316,085	3		311,758	3
2600	Other non-current liabilities			6	-		294	-
25XX	Total non-current liabilities			437,931	4		433,386	4
2XXX	Total liabilities			1,146,325	10		1,149,479	10
Equity								
	Capital	6(17)						
3110	Common stock			3,060,516	28		3,043,358	26
	Capital reserve	6(18)						
3200	Capital surplus			7,830,216	70		7,734,141	65
	Accumulated deficit	6(19)						
3350	Accumulated deficit		(	915,208)	(8)	(	115,540)	(1)
	Other equity interest							
3400	Other equity interest			41,939	-		20,919	-
3XXX	Total equity			10,017,463	90		10,682,878	90
	Significant contingent liabilities and unrecognised contract commitments	9						
	Significant events after the balance sheet date	11						
3X2X	Total liabilities and equity		\$	11,163,788	100	\$	11,832,357	100

The accompanying notes are an integral part of these parent company only financial statements.



EIRGENIX INC.
PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2023 AND 2022

(Expressed in thousands of New Taiwan dollars, except for loss per share)

		Year ended December 31			
Items	Notes	2023		2022	
		AMOUNT	%	AMOUNT	%
4000 Operating Revenue	6(20) and 7	\$ 1,022,653	100	\$ 1,481,017	100
5000 Operating Costs	6(5)(11)(25) and 7	(785,912)	(77)	(724,565)	(49)
5900 Gross Profit		<u>236,741</u>	<u>23</u>	<u>756,452</u>	<u>51</u>
Operating Expenses	6(11)(25) and 7				
6100 Sales and marketing expenses		(62,593)	(6)	(51,130)	(4)
6200 General and administrative expenses		(254,196)	(25)	(236,675)	(16)
6300 Research and development expenses		(955,346)	(94)	(802,439)	(54)
6450 Reversal of credit impairment loss(expected credit impairment loss)	12(2)	-	-	392	-
6000 Total operating expenses		<u>(1,272,135)</u>	<u>(125)</u>	<u>(1,089,852)</u>	<u>(74)</u>
6900 Operating Loss		<u>(1,035,394)</u>	<u>(102)</u>	<u>(333,400)</u>	<u>(23)</u>
Non-operating Income and Expenses					
7100 Interest income	6(3)(21)	134,471	13	59,584	4
7010 Other income	6(22)	5,439	1	37,644	3
7020 Other gains and losses	6(2)(23)	(11,180)	(1)	128,915	9
7050 Finance costs	6(10)(24) and 7	(10,403)	(1)	(9,635)	(1)
7070 Share of profit of subsidiaries , associates and joint ventures accounted for using equity method	6(8)	<u>2,324</u>	<u>-</u>	<u>1,690</u>	<u>-</u>
7000 Total non-operating income and expenses		<u>120,651</u>	<u>12</u>	<u>218,198</u>	<u>15</u>
7900 Loss before Income Tax		<u>(914,743)</u>	<u>(90)</u>	<u>(115,202)</u>	<u>(8)</u>
7950 Income tax	6(26)	(465)	-	(338)	-
8200 Net Loss		<u>(\$ 915,208)</u>	<u>(90)</u>	<u>(\$ 115,540)</u>	<u>(8)</u>
Other Comprehensive Income					
Components of other comprehensive income that will not be reclassified to profit or loss					
8316 Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	6(7)	<u>\$ 45,939</u>	<u>5</u>	<u>\$ 59,091</u>	<u>4</u>
8310 Other comprehensive income(loss) that will not be reclassified to profit or loss		<u>45,939</u>	<u>5</u>	<u>59,091</u>	<u>4</u>
Components of other comprehensive income that will be reclassified to profit or loss					
8361 Exchange differences on translation of foreign financial statements		220	-	220	-
8399 Income tax relating to components of other comprehensive income that will be reclassified to profit or loss	6(26)	(41)	-	-	-
8360 Other comprehensive income(loss) that will be reclassified to profit or loss		<u>179</u>	<u>-</u>	<u>220</u>	<u>-</u>
8300 Other Comprehensive Income		<u>\$ 46,118</u>	<u>5</u>	<u>\$ 59,311</u>	<u>4</u>
8500 Total Comprehensive Loss		<u>(\$ 869,090)</u>	<u>(85)</u>	<u>(\$ 56,229)</u>	<u>(4)</u>
Loss per share	6(27)				
9750 Loss per share		<u>(\$ 3.00)</u>	<u>(\$ 0.38)</u>		

The accompanying notes are an integral part of these parent company only financial statements.



EIRGENIX INC.
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2023 AND 2022
(Expressed in thousands of New Taiwan dollars)

Capital Reserves										Other equity interest			
									Exchange differences on translation of foreign financial statements	Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	Unearned compensation	Total equity	
Notes	Common stock	Additional paid-in capital	Donated assets received	Employee stock options	Capital surplus, stock options	Restricted stock to employees	Capital surplus, others	Accumulated deficit					
Year ended December 31, 2022													
Balance at January 1, 2022	\$ 3,003,845	\$ 10,313,563	\$ 2,036	\$ 41,958	\$ 3,467	\$ 114,928	\$ -	(\$ 2,973,500)	(\$ 237)	\$ 5,831	(\$ 83,140)	\$ 10,428,751	
Loss for 2022	-	-	-	-	-	-	-	(115,540)	-	-	-	(115,540)	
Other comprehensive income (loss)	6(7)	-	-	-	-	-	-	-	220	59,091	-	59,311	
Total comprehensive income (loss)	-	-	-	-	-	-	-	(115,540)	220	59,091	-	(56,229)	
Capital surplus used to offset accumulated deficit	6(19)	-	(2,971,464)	(2,036)	-	-	-	2,973,500	-	-	-	-	
Compensation costs of share-based payments	6(16)	-	-	-	61,651	-	871	-	-	-	92,790	155,312	
Employee stock options exercised	6(16)(17)	10,523	26,467	(8,320)	-	-	-	-	-	-	-	28,670	
Issuance of employee restricted stocks	6(16)(17)	6,318	-	-	-	47,318	-	-	-	-	(53,636)	-	
Redemption of employee restricted stocks	6(16)(17)	(2,260)	-	-	-	2,260	-	-	-	-	-	-	
Restricted stocks vested		-	59,358	-	-	(59,358)	-	-	-	-	-	-	
Conversion of convertible bonds	6(17)	24,932	104,904	-	(3,462)	-	-	-	-	-	-	126,374	
Redemption of convertible bonds		-	-	-	(5)	-	5	-	-	-	-	-	
Balance at December 31, 2022	\$ 3,043,358	\$ 7,532,828	\$ -	\$ 95,289	\$ -	\$ 105,148	\$ 876	(\$ 115,540)	(\$ 17)	\$ 64,922	(\$ 43,986)	\$ 10,682,878	
Year ended December 31, 2023													
Balance at January 1, 2023	\$ 3,043,358	\$ 7,532,828	\$ -	\$ 95,289	\$ -	\$ 105,148	\$ 876	(\$ 115,540)	(\$ 17)	\$ 64,922	(\$ 43,986)	\$ 10,682,878	
Loss for 2023	-	-	-	-	-	-	-	(915,208)	-	-	-	(915,208)	
Other comprehensive income (loss)	6(7)	-	-	-	-	-	-	-	179	45,939	-	46,118	
Total comprehensive income (loss)	-	-	-	-	-	-	-	(915,208)	179	45,939	-	(869,090)	
Capital surplus used to offset accumulated deficit	6(19)	-	(114,664)	-	-	-	(876)	115,540	-	-	-	-	
Compensation costs of share-based payments	6(16)	-	-	-	84,285	-	-	-	-	-	96,615	180,900	
Employee stock options exercised	6(16)(17)	7,270	25,769	(10,264)	-	-	-	-	-	-	-	22,775	
Employee stock options expired	6(16)	-	-	(1,810)	-	-	1,810	-	-	-	-	-	
Issuance of employee restricted stocks	6(16)(17)	11,818	-	-	-	109,895	-	-	-	-	(121,713)	-	
Redemption of employee restricted stocks	6(16)(17)	(1,930)	-	-	-	1,930	-	-	-	-	-	-	
Restricted stocks vested		-	71,119	-	-	(71,119)	-	-	-	-	-	-	
Balance at December 31, 2023	\$ 3,060,516	\$ 7,515,052	\$ -	\$ 167,500	\$ -	\$ 145,854	\$ 1,810	(\$ 915,208)	\$ 162	\$ 110,861	(\$ 69,084)	\$ 10,017,463	

The accompanying notes are an integral part of these parent company only financial statements.



EIRGENIX INC.
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2023 AND 2022
 (Expressed in thousands of New Taiwan dollars)

		Year ended December 31	
	Notes	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES			
Loss before tax		(\$ 914,743)	(\$ 115,202)
Adjustments			
Adjustments to reconcile profit (loss)			
Depreciation	6(9)(10)(25)	227,208	187,987
Amortization	6(11)(25)	11,296	16,184
Net loss (gain) on financial assets or liabilities at fair value	6(2)(23)	1,122	(2,863)
Interest expense	6(24)	10,403	9,635
Interest income	6(21)	(134,471)	(59,584)
Dividend income	6(22)	(475)	-
Compensation costs of share-based payments	6(16)(25)	180,900	155,312
Share of profit of subsidiaries 、 associates and joint ventures accounted for using equity method	6(8)	(2,324)	(1,690)
Loss on lease modification	6(10)(23)	413	709
Reversal of credit impairment loss (expected credit impairment loss)	12(2)	-	(392)
Loss on redemption of convertible bonds	6(23)	-	3
Changes in operating assets and liabilities			
Changes in operating assets			
Contract assets		(59,295)	(63,802)
Notes receivable, net		(19)	1,139
Accounts receivable, net		(220,608)	46,084
Accounts receivable, net-related parties		(2,636)	546
Other receivables		6,736	(13,793)
Inventories		58,826	(324,025)
Prepayments		29,825	(16,719)
Other current assets		-	1,555
Changes in operating liabilities			
Contract liabilities		(93,709)	(93,551)
Accounts payable		(55,051)	48,151
Other payables		7,338	19,212
Other payables - related parties		4,354	5,601
Other current liabilities		(169)	(1,816)
Cash outflow generated from operations		(945,079)	(201,319)
Interest received		132,183	55,232
Interest paid		(10,393)	(9,314)
Dividends received		475	-
Income tax received		1,128	-
Income tax paid		(12,813)	(4,835)
Net cash flows used in operating activities		(834,499)	(160,236)

(Continued)



EIRGENIX INC.
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2023 AND 2022
(Expressed in thousands of New Taiwan dollars)

		Year ended December 31	
	Notes	2023	2022
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of financial assets at fair value through profit or loss	6(2) and 7	\$ -	(\$ 58,390)
Acquisition of financial assets at fair value through other comprehensive income	6(7)	(623)	(208,627)
Acquisition of financial assets at amortised cost		(3,700,000)	(1,032,516)
Proceeds from disposal of financial assets at amortised cost		4,200,403	1,636,640
Acquisition of property, plant and equipment	6(28)	(575,239)	(345,548)
Acquisition of intangible assets	6(28)	(15,142)	(8,652)
Decrease in other financial assets		-	27,334
Decrease (increase) in refundable deposits (shown as other non-current assets)		56,253	(778)
Increase in prepayments for investments (shown as other non-current assets)		(46,270)	(20,000)
Increase in prepayments for business facilities (shown as other non-current assets)	6(9)	(138,453)	(433,952)
Increase in other non-current assets		-	(31,274)
Net cash flows used in investing activities		(219,071)	(475,763)
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Repayments of bonds	6(29)	-	(200)
Proceeds from long-term borrowings	6(29)	-	120,460
Decrease (increase) in guarantee deposits received (shown as other non-current liabilities)	6(29)	(288)	294
Repayments of lease principal	6(29)	(29,307)	(23,657)
Employee stock options exercised		22,775	28,669
Net cash flows (used in) from financing activities		(6,820)	125,566
Net decrease in cash and cash equivalents		(1,060,390)	(510,433)
Cash and cash equivalents at beginning of year		6,108,994	6,619,427
Cash and cash equivalents at end of year		\$ 5,048,604	\$ 6,108,994

The accompanying notes are an integral part of these parent company only financial statements.

2023 Deficit Offset Statement

	In NTD
Undistributed Earnings in the beginning of the year	-
2023 Net loss after tax	(915,207,770)
Capital Surplus-Others	1,809,750
Capital Surplus-Additional Paid-In Capital	913,398,020
Deficit to be offset at the end of the year	-
Chairman: Lee-Cheng Liu Officer: Lee-Cheng Liu Head of the Accounting Dept.: Hsiu-Chuan Yang	

Comparison Table for the Rules of Procedure for Shareholders Meetings

After the Revision	Before the Revision	Explanation
Article 8 Convening a shareholders meeting, this Corporation shall prepare electronic versions of the shareholders meeting notice and proxy forms, and the origins of and explanatory materials relating to all proposals, including proposals for ratification, matters for deliberation, or the election or dismissal of directors, and upload them to the Market Observation Post System (MOPS) before 30 days before the date of a regular shareholders meeting or before 15 days before the date of a special shareholders meeting. This Corporation shall prepare electronic versions of the shareholders' meeting agenda and supplemental meeting materials and upload them to the MOPS. before 21 days before the date of the regular shareholder's meeting or before 15 days before the date of the special shareholder's meeting <u>by complying with relevant laws and regulations.</u> However, if the company's paid-in capital at the end of the most recent fiscal year is NT\$10 billion or	Article 8 Convening a shareholders meeting, this Corporation shall prepare electronic versions of the shareholders meeting notice and proxy forms, and the origins of and explanatory materials relating to all proposals, including proposals for ratification, matters for deliberation, or the election or dismissal of directors, and upload them to the Market Observation Post System (MOPS) before 30 days before the date of a regular shareholders meeting or before 15 days before the date of a special shareholders meeting. This Corporation shall prepare electronic versions of the shareholders' meeting agenda and supplemental meeting materials and upload them to the MOPS before 21 days before the date of the regular shareholder's meeting or before 15 days before the date of the special shareholder's meeting. However, if the company's paid-in capital at the end of the most recent fiscal year is NT\$10 billion or more, or the total shareholding ratio of foreign and	The revisions to those Article are proposed in accordance with the amendment to “Regulations Governing Content and Compliance Requirements for Shareholders' Meeting Agenda Handbooks of Public Companies” by the ruling letter JinGuan-Zheng-Fa-Zi No. 1120385664 dated December 8, 2023, issued by the Financial Supervisory Commission.

After the Revision	Before the Revision	Explanation
more, or the total shareholding ratio of foreign and Mainland China shareholders recorded in the shareholder register is more than 30% at the regular shareholders meeting in the most recent fiscal year, the upload of foregoing electronic versions should be completed before 30 days before the shareholders' meeting. In addition, 15 days before the date of the shareholders' meeting, This Corporation shall also have prepared the shareholders' meeting agenda and supplemental meeting materials and made them available for review by shareholders at any time. The meeting agenda and supplemental materials shall also be displayed at this Corporation and the professional shareholder services agent designated thereby. (Omitted)	Mainland China shareholders recorded in the shareholder register is more than 30% at the regular shareholders meeting in the most recent fiscal year, the upload of foregoing electronic versions should be completed before 30 days before the shareholders' meeting. In addition, 15 days before the date of the shareholders' meeting, this Corporation shall also have prepared the shareholders' meeting agenda and supplemental meeting materials and made them available for review by shareholders at any time. The meeting agenda and supplemental materials shall also be displayed at this Corporation and the professional shareholder services agent designated thereby. (Omitted)	
Article 20 These Rules were enacted on Jul. 24, 2013 Amended on Sep. 13, 2016 for the first time. Amended on Jun. 12, 2018 for the second time. Amended on Jun. 29, 2020 for the third time. Amended on Aug. 3, 2021 for the fourth time. Amended on Jun. 10, 2022 for the fifth time. <u>Amended on May 30, 2024 for the</u>	Article 20 These Rules were enacted on Jul. 24, 2013 Amended on Sep. 13, 2016 for the first time. Amended on Jun. 12, 2018 for the second time. Amended on Jun. 29, 2020 for the third time. Amended on Aug. 3, 2021 for the fourth time. Amended on Jun. 10, 2022 for the fifth time.	Add the date of amendments.

After the Revision	Before the Revision	Explanation
<u>sixth time.</u>		